Zobrazeno 1 - 10
of 708
pro vyhledávání: '"Pili R"'
Publikováno v:
In Renewable and Sustainable Energy Reviews December 2020 134
Publikováno v:
In Renewable Energy December 2020 161:676-690
Autor:
Rupert C., Dell' Aversana C., Mosca L., Montanaro V., Arcaniolo D., De Sio M., Bilancio A., Altucci L., Palinski W., Pili R., de Nigris F.
Publikováno v:
Journal of experimental & clinical cancer research : CR, vol 42, iss 1
Background Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cancer. Large-scale metabolomic data have associated metabolic alterations with the pathogenesis and progression of renal carcinoma and have correlated mitochondri
Autor:
Drakaki, A., Powles, T.B., Wang, Y., Bupathi, M., Joshi, M., Fleming, M.T., Gomez de Liano Lista, A., Morales Barrera, R., Pili, R., Boulos, S., Shrestha, Y.
Publikováno v:
In Annals of Oncology September 2024 35 Supplement 2:S1140-S1140
Autor:
Kyriakopoulos, C., Chatta, G., Laccetti, A.L., Iannotti, N., Sokolova, A.O., Hotte, S.J., Tutrone, R., Markowski, M.C., Nordquist, L.T., Pili, R., Saad, F., Zhang, J., Villaluna, K., Younginger, B., Le Moigne, R., Cesano, A.
Publikováno v:
In Annals of Oncology September 2024 35 Supplement 2:S990-S990
Autor:
Morris, M.J. *, Eisenberger, M.A., Pili, R., Denmeade, S.R., Rathkopf, D., Slovin, S.F., Farrelly, J., Chudow, J.J., Vincent, M., Scher, H.I., Carducci, M.A.
Publikováno v:
In Annals of Oncology October 2012 23(10):2714-2719
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Laccetti, A.L., Chatta, G., Kyriakopoulos, C., Iannotti, N., Hotte, S.J., Markowski, M.C., Pili, R., Vuky, J., Zhang, J., Saad, F., Villaluna, K., Younginger, B., Le Moigne, R., Cesano, A.
Publikováno v:
In Annals of Oncology October 2023 34 Supplement 2:S982-S983
The organic Rankine cycle power system is an emerging technology, which is able to recover the waste heat from the diesel engine of heavy-duty trucks and thus increase the overall engine efficiency. One of the major technical challenges for the integ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______518::5136c17b4e9bcc3aac8f91a92672ef21
https://mediatum.ub.tum.de/1633653
https://mediatum.ub.tum.de/1633653
Autor:
Voss M, Gordon M, Mita M, Rini B, Makker V, Macarulla T, Smith D, Cervantes A, Puzanov I, Pili R, Wang D, Jalal S, Pant S, Patel M, Neuwirth R, Enke A, Shou Y, Sedarati F, Faller D, Burris H
Publikováno v:
BRITISH JOURNAL OF CANCER
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Background This Phase 1 dose-escalation/expansion study assessed safety/tolerability of sapanisertib, an oral, highly selective inhibitor of mTORC1/mTORC2, in advanced solid tumours. Methods Eligible patients received increasing sapanisertib doses on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::3cd2f479360b3bf2c4ae13e196897a9a
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15559
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15559